^
HER-2 L755S
Breast Cancer
neratinib
Resistant: D – Preclinical
Cancer Res - 3 days - (New D)
HER-2 G778_P780dup
Breast Cancer
HM 78136B
Sensitive: D – Preclinical
Cancer Res - 3 days - (New D)
HER-2 L755S
Breast Cancer
HM 78136B
Sensitive: D – Preclinical
Cancer Res - 3 days - (New D)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
Anticancer Drugs - 6 days - (New C3)
HR positive
HER2 Negative Breast Cancer
abemaciclib
Sensitive: A1 - Approval
Precision Oncology News - 1 week - (New A2)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pyrotinib
Sensitive: B - Late Trials
Clin Cancer Res - 1 week - (New C3)
TMB-H
Triple Negative Breast Cancer
durvalumab
Sensitive: C3 – Early Trials
Clin Cancer Res - 1 week - (New C3)
No biomarker
Triple Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
Everest Medicines Press Release - 2 weeks - (New A1)
BRCA2 mutation + HR positive
HER2 Negative Breast Cancer
olaparib
Sensitive: A2 - Guideline
Medicine (Baltimore) - 2 weeks - (New C4)
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
CNS Oncol - 2 weeks - (New C4)
ER positive
Estrogen Receptor Positive Breast Cancer
ABSK091
Sensitive: C3 – Early Trials
Nat Commun - 2 weeks - (New C3)
RB1 deletion
Estrogen Receptor Positive Breast Cancer
IGM-9427
Sensitive: D – Preclinical
Oncogene - 2 weeks - (New D)
RB1 deletion
Estrogen Receptor Positive Breast Cancer
WEE1 inhibitor + Aurora kinase inhibitor
Sensitive: D – Preclinical
Oncogene - 2 weeks - (New D)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + abemaciclib
Sensitive: A2 - Guideline
ASCO.org - 3 weeks - (New A2)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: A2 - Guideline
ASCO.org - 3 weeks - (New A2)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
ASCO.org - 3 weeks - (New A2)
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
ASCO.org - 3 weeks - (New A2)
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: A1 - Approval
Mol Clin Oncol - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
lapatinib
Sensitive: A2 - Guideline
ASCO.org - 3 weeks - (New A2)
HER-2 underexpression
Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: B - Late Trials
N Engl J Med - 3 weeks - (New B)
ER positive
HER2 Negative Breast Cancer
AZD5363
Sensitive: C3 – Early Trials
Lancet Oncol - 3 weeks - (New C3)
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
No biomarker
Breast Cancer
TAC
Sensitive: A1 - Approval
HR positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HR positive
HER2 Negative Breast Cancer
ribociclib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive: A1 - Approval
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: A1 - Approval
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Breast Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Breast Cancer
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
No biomarker
Breast Cancer
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
ribociclib
Sensitive: A1 - Approval
ER negative
Breast Cancer
toremifene
Resistant: A1 - Approval
No biomarker
Breast Cancer
toremifene
Sensitive: A1 - Approval
No biomarker
Breast Cancer
albumin-bound paclitaxel
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
lapatinib
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Negative Breast Cancer
trastuzumab + lapatinib
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
lapatinib
Sensitive: A1 - Approval
HR positive
HER2 Negative Breast Cancer
everolimus
Sensitive: A1 - Approval
BRCA2 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: A1 - Approval
BRCA1 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
trastuzumab
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel + capecitabine
Sensitive: A1 - Approval
No biomarker
Breast Cancer
capecitabine
Sensitive: A1 - Approval
HR positive
HER2 Positive Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: A1 - Approval
No biomarker
Breast Cancer
eribulin mesylate
Sensitive: A1 - Approval
No biomarker
Breast Cancer
non-pegylated liposomal doxorubicin
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
trastuzumab / hyaluronidase-oysk
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
olaparib
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
No biomarker
Breast Cancer
bevacizumab
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
exemestane
Sensitive: A1 - Approval
No biomarker
Breast Cancer
exemestane
Sensitive: A1 - Approval
No biomarker
Breast Cancer
letrozole
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
letrozole
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
anastrozole
Sensitive: A1 - Approval
No biomarker
Breast Cancer
anastrozole
Sensitive: A1 - Approval
ER negative
Breast Cancer
anastrozole
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
toremifene
Sensitive: A1 - Approval
HER-2 amplification
Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Breast Cancer
ixabepilone
Sensitive: A1 - Approval
BRCA1 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
BRCA2 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
Breast Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
talazoparib
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
fulvestrant
Sensitive: A1 - Approval
HR positive
HER2 Negative Breast Cancer
fulvestrant
Sensitive: A1 - Approval
No biomarker
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Breast Cancer
leuprolide acetate for depot suspension
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
trastuzumab + docetaxel
Sensitive: A1 - Approval
No biomarker
Breast Cancer
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Breast Cancer
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
TCHP
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
CaT
Sensitive: A2 - Guideline
ER positive
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: A2 - Guideline